



Vandana Abramson, MD

“Successfully developing immunotherapy for breast cancer will be best achieved through a collaborative effort of scientists, clinical investigators and patients. To advance immunotherapy for patients with metastatic triple negative breast cancer, we need to better understand the immunobiology of triple negative breast cancer and investigate combinations of various anti-cancer agents - both are aims of this phase II trial.”

- Jennifer A. Pietenpol, PhD



Jennifer A. Pietenpol, PhD

Evaluation of Combination Therapy for Metastatic Triple Negative Breast Cancer

STUDY TITLE: A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer

TRIAL NUMBER: NCT03206203

FOCUS: [Treatment](#)

TRIAL PHASE: [Phase II \(Phase 2\)](#)

WHAT HAPPENS IN THIS STUDY?

This study’s goal is to test whether the outcomes for people living with metastatic triple negative breast cancer can be improved by treating them with a combination of the [immunotherapy](#) drug atezolizumab (Tecentriq®) and the [chemotherapy](#) drug carboplatin (Paraplatin®). This combination will be compared to carboplatin alone, which is a current standard of care.

This is a [randomized trial](#), meaning that neither the physician nor the participant choose the treatment group. Instead, participants will be assigned by chance to receive either carboplatin alone or carboplatin plus atezolizumab.

ARE YOU ELIGIBLE?

This is a study for women or men who have been diagnosed with [metastatic](#) (stage IV) [triple negative](#) (ER-/PR-/HER2-) breast cancer. PD-L1 testing is not needed to participate in this study, but prior immunotherapy is not allowed.

The status of this study is subject to change. To see the most current information, visit [breastcancertrials.org](#) or [clinicaltrials.gov](#).

WHAT WILL THIS MEAN FOR PATIENTS?

This study offers those involved the chance to receive a new combination therapy for metastatic triple negative breast cancer. It will help researchers decide if giving both drugs together works better to stop the growth and spread of cancer cells. Participants will be contributing to cancer research that may one day help improve the treatment of breast cancer for others.

WHO DO I CONTACT ABOUT THIS STUDY?

LEAD TRIAL PI AND TRIAL LOCATION:

Vandana Abramson, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States, Vanderbilt Clinical Trials Information Program, 1-800-811-8480, cip@vanderbilt.edu

OTHER STUDY LOCATIONS:

This study is offered at many sites across the country. See if there is a [research site](#) near you.

KOMEN CONNECTION

Jennifer Pietenpol, PhD, is one of Komen’s [Chief Scientific Advisors](#) and the Principal Investigator (PI) for this study’s correlative research. She will use tumor samples to help understand if there are different responses to treatment based on tumor characteristics. Dr. Pietenpol is working with lead PI, Dr. Abramson, and other collaborators at Vanderbilt-Ingram Cancer Center. They want to learn more about metastatic triple negative breast cancer to identify biological markers. These markers may indicate how a person will respond to treatment and if they will become resistant to treatment. Her work will help oncologists determine the most appropriate care for each patient.

BREAST CANCER CLINICAL TRIAL INFORMATION HELPLINE

Call our clinical trial information helpline at 1-877 GO KOMEN (1-877-465-6636) or email at clinicaltrialinfo@komen.org to talk with a trained specialist. Our caring and trained staff provide support and education about clinical trials to help people gain a better understanding of clinical trials.

Disclaimer

This information is being provided for education purposes only and does not contain all information related to this clinical study. The study status and eligibility criteria may change. If you are interested in learning if this study is right for you, please reach out to the study coordinator or your doctor for more information.